Pharmacy Articles

Pharmacy

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Boehringer Ingelheim will present new data on the company's two lead oncology compounds, BIBW 2992 and BIBF 1120 at the 2009 Annual Meeting of the American Society of Clinical Oncology, the company announced today. Two studies in the LUX-Lung clinical development programme for BIBW 2992 and a Phase II study of BIBF 1120 in ovarian cancer patients will be presented.

Today in Chemotherapy/Oncology...keeping you current

Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics
Expert Opinion on Investigational Drugs, 12/16/09

Plerixafor for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma and Multiple Myeloma
Annals of Pharmacotherapy, 12/16/09

Clinically-Staged T3N0 Rectal Cancer: Is Preoperative Chemoradiotherapy the Optimal Treatment
Annals of Surgical Oncology, 12/16/09

Today in Other Drugs...keeping you current

A Clinical Review of Echinocandins in Pediatric Patients
Annals of Pharmacotherapy, 12/16/09

Use of psychotropic drugs and analgesics among users of antiobesity drugs - a population based study
Pharmacoepidemiology and Drug Safety, 12/16/09

Measuring exacerbations in obstructive lung disease
Pharmacoepidemiology and Drug Safety, 12/16/09


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address